Pomerantz Law Firm Launches Investigation into Insmed Incorporated for Potential Securities Fraud

Pomerantz LLP, a renowned law firm specializing in corporate, securities, and antitrust class litigation, is currently investigating claims on behalf of investors of Insmed Incorporated (NASDAQ: INSM). The focus of this investigation is whether Insmed, along with some of its officers or directors, may have been involved in securities fraud or other illegal business practices.

On December 17, 2025, Insmed published a troubling press release announcing the results of its Phase 2b BiRCh study concerning brensocatib in patients suffering from chronic rhinosinusitis without nasal polyps (CRSsNP). The study unfortunately fell short of meeting both its primary and secondary efficacy endpoints across the treatment arms of 10 mg and 40 mg. As a result, Insmed made the decision to terminate further development of brensocatib.

Following this announcement, Insmed's stock experienced a significant drop, plummeting by $31.91 per share, which translates to a staggering 16.08%, bringing the closing price down to $166.55 on December 18, 2025. Such a sudden and steep decline has drawn the attention of both investors and legal experts, triggering this new wave of scrutiny from Pomerantz LLP.

Investors who feel they may have been impacted by this decline are encouraged to reach out to Danielle Peyton at the firm. This call to action is crucial for those who believe they have experienced losses related to their investments in Insmed. The contact information provided includes an email and a direct line where concerned parties can inquire about joining a possible class action lawsuit.

Pomerantz LLP has a commendable history of advocating for victims of securities fraud and corporate misconduct, having secured numerous multimillion-dollar settlements in cases throughout its over 85-year tenure. The firm was founded by the late Abraham L. Pomerantz, known as the dean of class action bar, who revolutionized the field of securities class actions. Today, Pomerantz maintains this legacy, representing investors in various allegations including breaches of fiduciary duties.

For individuals who have incurred losses due to Insmed's alleged misleading statements or actions, it is vital to engage with legal counsel as soon as possible to explore their rights and potential for recuperating damages. Legal experts believe that the developments surrounding Insmed may uncover deeper issues affecting investors' financial standings and reinforce the importance of corporate governance.

In light of the recent findings, it is essential for investors to stay updated on any developments regarding Insmed's situation, as well as the outcomes of the ongoing investigation by Pomerantz LLP. The firm remains vigilant in its pursuit of justice on behalf of investors and is expected to provide further insights into the case as it unfolds.

If you believe you have been affected by the performance of Insmed in light of these events, contacting Pomerantz LLP could be your first step in holding any responsible parties accountable.